Business StandardCenter·
India's pharma ambitions are running into a regulatory capacity constraint
Govt's decision under the ₹10,000 cr Biopharma SHAKTI programme to create a dedicated scientific review cadre within CDSCO is an important reform
Read at Business Standard →

